P148 JAK-inhibition by Baricitinib and Tofacitinib Ameliorates Pathological Bone Loss

doi 10.1136/annrheumdis-2018-ewrr2019.131
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

958 Pharmacological Inhibition of JAK/STAT Signaling by Tofacitinib Prevents Organ Fibrosis: Novel Therapy for Scleroderma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Naringin Ameliorates Bone Loss Induced by Sciatic Neurectomy and Increases Semaphorin 3A Expression in Denervated Bone

Scientific Reports
Multidisciplinary
2016English

Inhibition of Bone Morphogenetic Protein 6 Receptors Ameliorates Sjögren’s Syndrome in Mice

Scientific Reports
Multidisciplinary
2020English

Effect of Janus Kinase Inhibition by Tofacitinib on Body Composition and Glucose Metabolism

Journal of Medical Investigation
BiochemistryMedicineGeneticsMolecular Biology
2018English

Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss via Suppressing Osteoclastogenesis in Mice

Frontiers in Pharmacology
Pharmacology
2019English

Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2014English

JAK Inhibition and Symptom Control in Myeloproliferative Neoplasms

Current Medical Research and Opinion
Medicine
2018English

Stemming Bone Loss by Suppressing Apoptosis

Journal of Clinical Investigation
Medicine
1999English

JAK Inhibition by Methotrexate (And csDMARDs) May Explain Clinical Efficacy as Monotherapy and Combination Therapy

Journal of Leukocyte Biology
AllergyImmunologyCell Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy